HSPA1A and hepatocellular carcinoma: Zhang et al. demonstrated that the nanoemulsion-encapsulated MAGE1-MAGE3-MAGEn/HSP70 fusion protein vaccine elicited stronger immune responses than those without nanoemulsion-encapsulation in hepatocellular carcinoma, suggesting that this novel nanoemulsion carrier induces potent anti-tumor immunity against the encapsulated antigens [198].